seattletimes.com

seattletimes.com
Share

seattletimes.com

 •  December 16, 2017

The rising cost of medications and the lack of regulation on drug marketing and lobbying is putting life-sustaining medications out of reach. I know; I was diagnosed with Type 1 Diabetes at 4 years old. Paying for my supplies throughout childhood was made affordable given my parents’ health insurance. Unfortunately, when I aged out of their plan...

seattletimes.com

 •  September 21, 2017

COLUMBUS, Ohio (AP) — A member of the famed Tuskegee Airmen is joining other military veterans in supporting a fall ballot measure in Ohio that would bar state agencies from buying drugs at prices higher than those paid by the Department of Veterans Affairs. Don Elder attended a Statehouse news conference Thursday organized by the vote-yes...

seattletimes.com

 •  June 26, 2017

Seattle Genetics is announcing Monday results of a clinical trial showing patients with advanced Hodgkin lymphoma do better when its drug Adcetris replaces one of the four drugs in the current first-line treatment for the cancer. That sets the stage for seeking Food and Drug Administration approval for the treatment “as soon as possible,” said Clay...

seattletimes.com

 •  June 19, 2017

Seattle Genetics said it is discontinuing a Phase 3 clinical trial after data showed “a higher rate of deaths, including fatal infections” in acute myeloid leukemia patients receiving its drug than in the study’s other patients. As a result of the data it received June 16, the company said Monday, Seattle Genetics is suspending patient enrollment...

seattletimes.com

 •  April 14, 2017

Seattle-based M3 Biotechnology has raised $12 million from investors, and plans to use the funds to start clinical trials for a drug that seeks to reverse the effects of Alzheimer’s disease. The startup has licensed technology developed over more than a decade at Washington State University, and has been working for the past three years to develop...

seattletimes.com

 •  March 1, 2017

Juno Therapeutics is shutting down the clinical trial of one of its cancer drugs, three months after it was put on hold following patient deaths. The Seattle biotech will permanently stop the “Rocket” trial of JCAR015 to treat acute lymphoblastic leukemia (ALL) in adults. “We have decided not to move forward … at this time, even though it generated...